Animal Virus Entry and Replication Strategies

Animal virus infection begins with attachment: a viral surface protein binds a specific host-cell receptor, a molecule the cell normally uses for its own signaling, adhesion, or transport. This binding event is the molecular basis of tropism — why poliovirus infects neurons and gut epithelium but not muscle, why HIV infects CD4+ T cells and macrophages but not red blood cells. Attachment alone does not deliver the genome across a membrane; that requires penetration, the physical crossing of the plasma membrane or an endosomal membrane. Enveloped viruses penetrate by membrane fusion, merging their lipid envelope with a host membrane. Naked viruses penetrate by permeabilizing a membrane just enough to inject their genome, or by rupturing it outright. After penetration comes uncoating: the stepwise, often partial, disassembly of the capsid or nucleocapsid that exposes the genome to the machinery it needs — ribosomes for translation, polymerases for replication, or nuclear import machinery for viruses that replicate in the nucleus. Uncoating is rarely instantaneous or complete; many viruses retain a core or subviral particle well into replication, and dismantling too early or too late both abort infection. This graded, checkpoint-like character means uncoating is now understood less as a single reaction and more as a coordinated program triggered by sequential cellular cues — pH, ions, chaperones, motor proteins. The whole entry process culminates in genome delivery to the correct subcellular compartment, at which point the logic of the Baltimore Classification System takes over to explain replication. Later, newly made genomes and structural proteins must leave the cell as egress, which for enveloped viruses usually means non-lytic budding from the plasma membrane or an internal organelle, and for naked viruses usually means cell lysis. This single structural distinction — envelope or no envelope — threads through the entire life cycle and is the organizing idea of this article.

Step 1 — Attachment. A viral attachment protein (a glycoprotein spike for enveloped viruses, a capsid surface loop or canyon for naked viruses) binds a specific cell-surface receptor with dissociation constants typically in the nanomolar range. Examples: influenza hemagglutinin binds sialic acid; HIV gp120 binds CD4 plus a chemokine coreceptor (CCR5 or CXCR4); rhinovirus capsid binds ICAM-1; poliovirus binds CD155 (PVR). Many viruses use co-receptors, requiring two sequential binding events before penetration can proceed — this two-step logic reduces accidental fusion and adds a layer of tropism control.

Step 2 — Penetration. Enveloped viruses use one of two fusion routes:

• Direct fusion at the plasma membrane, used by HIV and paramyxoviruses (e.g., measles, RSV). Receptor binding triggers an irreversible conformational change in the fusion glycoprotein, which springs out a hydrophobic fusion peptide that embeds in the host membrane, then folds back on itself (a "hairpin" or trimer-of-hairpins structure), physically pulling the viral and cell membranes together until they merge.
• Fusion from within an endosome, used by influenza, Zika, and many others. The virus is first taken up by receptor-mediated endocytosis; acidification of the endosome (pH drops from ~7.4 to ~5–6) triggers the same kind of fusion-peptide conformational change, now pH-triggered rather than receptor-triggered.

Naked viruses cannot fuse membranes (no envelope), so they use two alternative strategies:

• Membrane permeabilization without full engulfment: poliovirus, upon receptor binding at 37°C, undergoes a conformational expansion (forming a 135S "A-particle") that externalizes an internal capsid protein (VP4, plus the N-terminus of VP1), which inserts into the membrane to form a pore just wide enough for the RNA genome to thread through, leaving the empty capsid outside.
• Endocytosis followed by membrane lysis or pore formation from inside a vesicle: adenovirus is endocytosed, and low endosomal pH triggers capsid protein VI to be exposed and to lyse the endosomal membrane, releasing a partially disassembled capsid into the cytoplasm, which then traffics to the nuclear pore.

Step 3 — Uncoating. For RNA viruses replicating in the cytoplasm (most naked RNA viruses, e.g., poliovirus, and many enveloped RNA viruses like influenza's ribonucleoprotein complexes), uncoating exposes the genome, or a genome-polymerase complex, to ribosomes or the viral replicase. For viruses replicating in the nucleus (adenovirus, herpesviruses, influenza — unusually, for an RNA virus), the partially uncoated capsid docks at a nuclear pore complex, and the genome (or ribonucleoprotein) is imported through the pore, sometimes using host importin machinery. Herpesvirus capsids dock at the nuclear pore and eject DNA directly into the nucleoplasm through the pore channel, driven by the same internal pressure (tens of atmospheres) that packaged the DNA in the first place — a physical, not just chemical, uncoating.

Step 4 — Replication and assembly are governed by the genome type per the Baltimore Classification System, detailed separately in DNA Virus Replication Strategies and RNA Virus Replication Strategies.

Step 5 — Egress. Enveloped viruses acquire their envelope by budding through a cellular membrane — the plasma membrane (HIV, influenza), or an internal membrane such as the ER-Golgi intermediate compartment (herpesviruses' primary envelopment at the nuclear membrane, then a second envelopment event in the Golgi) — capturing host lipids and inserting their own glycoproteins as they bud. This can occur repeatedly over days without necessarily killing the cell immediately, though prolonged infection eventually causes damage covered in Viral Pathogenesis and Host Damage. Naked viruses generally cannot bud (there is no envelope to acquire), so progeny accumulate intracellularly until the cell lyses, releasing thousands of particles in a single burst — a strategy that trades sustained low-level output for a large, synchronized release.

Hershey and Chase (1952): genomes, not proteins, carry infectivity. Although performed with bacteriophage T2 rather than an animal virus, this experiment established the conceptual foundation for everything above and is foundational to all of virology. Hershey and Chase labeled one batch of phage with radioactive phosphorus-32 (which marks DNA, since DNA's backbone is phosphate-rich and proteins contain almost none) and another batch with radioactive sulfur-35 (which marks protein, since methionine and cysteine contain sulfur but DNA does not). They allowed each labeled phage population to infect E. coli, then agitated the mixture in a blender to shear off the phage "ghosts" (empty capsids) still attached to the cell surface, and centrifuged to separate cells from supernatant. Result: the majority of ³²P (DNA label) stayed with the infected cells and was passed to progeny phage, while the majority of ³⁵S (protein label) stayed in the supernatant with the empty capsids. This proved that the capsid remains outside the cell and only the genome enters — the first direct demonstration that penetration and uncoating separate genome from capsid, and that the genome alone is sufficient to redirect the host cell. Every subsequent entry study in animal virology is framed by this genome/capsid distinction.

Helenius, Marsh, and colleagues (1980–1985): endosomal acidification is required for influenza fusion. Direct evidence for pH-triggered membrane fusion came from a series of experiments using lysosomotropic weak bases. Ari Helenius and coworkers treated cells with ammonium chloride or chloroquine, drugs that buffer and raise the pH of endosomes without otherwise blocking endocytosis. Under these conditions, influenza virus was still endocytosed normally — electron microscopy showed virions inside endosomes — but infection was completely blocked; the viral genome never reached the cytoplasm, and viral protein synthesis did not occur. When the drug was washed out, infection proceeded. This showed that endocytic uptake alone is not sufficient for entry — an acidic environment inside the endosome is specifically required, implicating a pH-dependent conformational change in a viral protein. Subsequent biochemical and structural work identified that protein as hemagglutinin (HA): at neutral pH HA is a metastable, spring-loaded trimer; below about pH 5.5, HA undergoes an irreversible conformational change that projects the fusion peptide into the endosomal membrane and refolds HA into a highly stable hairpin, driving fusion. Structural biology (X-ray crystallography of HA at neutral versus low pH, from the 1980s–1990s, notably by Don Wiley's group) later confirmed the two conformations directly, closing the loop between the pharmacological experiment and the atomic mechanism.

Complementary evidence for poliovirus pore formation. Cryo-electron microscopy and biochemical studies (from the 1990s onward, including work from James Hogle's laboratory) showed that receptor (CD155) binding at 37°C converts the mature 160S poliovirus particle into an expanded 135S "A-particle," externalizing VP4 and the VP1 N-terminus, and that these externalized peptides insert into liposomal membranes in vitro, forming size-selective pores permeable to RNA but not to the folded capsid — directly demonstrating the "pore, not fusion" mechanism proposed for naked viruses.

Example 1 — Predicting tropism from receptor distribution. A researcher engineers three human cell lines: Line A expresses high levels of CD4 and CCR5, Line B expresses CD4 and CXCR4, and Line C expresses neither CD4 nor any HIV coreceptor but does express CCR5 alone. HIV-1 requires sequential binding: gp120 first binds CD4, and only after this CD4-induced conformational change does gp120 expose a site that binds a coreceptor (CCR5, used by "R5-tropic" macrophage-adapted strains, or CXCR4, used by "X4-tropic" strains that emerge later in infection). Given an R5-tropic viral isolate:

• Line A (CD4⁺CCR5⁺): infection proceeds — both binding steps satisfied.
• Line B (CD4⁺CXCR4⁺): CD4 binding occurs, but no CCR5 for R5-tropic virus to engage — entry blocked at the second step. (An X4-tropic isolate would infect Line B instead.)
• Line C (CD4⁻CCR5⁺): CCR5 alone is insufficient because gp120 cannot expose its coreceptor-binding site without prior CD4 engagement — entry blocked at the first step.

This reasoning explains, mechanistically, why CD4⁺ T cells and macrophages are the natural targets of HIV, why CCR5-Δ32 homozygotes (who lack functional CCR5) are highly resistant to R5-tropic HIV infection, and why the "Berlin patient" and "London patient" were functionally cured after receiving bone-marrow transplants from CCR5-Δ32 homozygous donors.

Example 2 — Calculating a one-step growth curve burst size. A virology class infects a monolayer of 2 × 10⁶ cells with poliovirus at a multiplicity of infection (MOI) of 0.01 plaque-forming units (PFU) per cell, ensuring most infected cells receive only a single virion (avoiding co-infection artifacts). After adsorption, unbound virus is washed away and cells are incubated. Viral titer in the supernatant is measured by plaque assay at intervals:

Number of cells initially infected = MOI × total cells = 0.01 × 2 × 10⁶ = 2 × 10⁴ cells. Total progeny released by plateau (10 h) = 2 × 10⁷ PFU. Burst size per infected cell = 2 × 10⁷ / 2 × 10⁴ = 1,000 PFU per cell. The flat titer between 0–4 h is the eclipse period: after penetration and uncoating, the genome has entered the cell but no infectious progeny yet exist — the virus is "invisible" to a plaque assay even though it is being actively replicated inside. This eclipse period is a direct experimental signature of uncoating: it exists precisely because the naked poliovirus genome, once it enters the cytoplasm, must first be translated and its replication complex assembled before any new infectious virions can form — the interval maps almost exactly onto the interval between penetration and the first burst of progeny assembly. Because poliovirus is a naked, lytic virus, all progeny release occurs in the single sharp burst between about 6 and 8 hours, contrasting with an enveloped budding virus (e.g., influenza), whose one-step curve shows a more gradual, sustained rise as virions bud continuously rather than in one lytic release.

Ari Helenius, a Finnish-American cell biologist, spent much of his career at Yale University dissecting how animal viruses physically enter cells, treating virions as precise molecular probes of endocytic and membrane trafficking pathways rather than merely as pathogens to be neutralized. Working alongside collaborators including Mark Marsh and Judith White in the late 1970s and 1980s, he combined pharmacological perturbation (lysosomotropic weak bases), biochemical fusion assays, and electron microscopy to show that influenza's genome delivery is gated by a specific pH threshold inside the endosome — reframing "entry" from a vague single event into a testable, quantifiable, multi-step cell-biological pathway. His broader research program used viruses systematically to map the entire endocytic and secretory system of the mammalian cell, an approach that made virus entry research a productive lens onto normal cell physiology, not just an isolated topic in pathogen biology.

Entry mechanisms are now first-line drug targets. Maraviroc blocks HIV gp120 from engaging CCR5, exploiting the two-step attachment logic described above; enfuvirtide (T-20) blocks the fusion-peptide hairpin formation of HIV gp41 directly. Oseltamivir and zanamivir target the enzyme neuraminidase, which is needed for influenza egress (cleaving sialic acid so budded virions can release from the cell surface rather than re-binding it), showing that egress, not just entry, is druggable. Understanding endosomal acidification directly enabled the design of chloroquine and hydroxychloroquine as candidate broad-spectrum entry inhibitors, though clinical efficacy against SARS-CoV-2 in humans proved disappointing despite in vitro activity — a caution that mechanism-based promise does not guarantee clinical translation. Receptor biology also underlies vaccine and gene-therapy design: adeno-associated virus (AAV) vectors are engineered with modified capsid surface loops to redirect tropism toward specific tissues (liver, retina, muscle) for gene therapy, directly manipulating the attachment step described above. Pseudotyping — swapping the envelope glycoprotein of one virus onto the core of another, as in VSV-G-pseudotyped lentiviral vectors — exploits the modularity of attachment/fusion machinery to broaden or restrict which cells a therapeutic vector can enter. Understanding naked-virus stability guides public health practice directly: because norovirus and poliovirus lack an envelope, alcohol-based hand sanitizers (which dissolve lipid envelopes but do not reliably inactivate protein capsids) are markedly less effective against them than soap-and-water handwashing, informing outbreak-control guidance in hospitals and cruise ships. Finally, egress mechanisms inform oncolytic virus design, where engineers select naked, lytic viruses specifically because their burst-release egress strategy destroys the infected tumor cell, tying entry and egress mechanics directly into cancer therapeutics and into the tissue-damage questions taken up in Viral Pathogenesis and Host Damage.

Ask the tutor: How does the pH-triggered conformational change in influenza hemagglutinin compare mechanistically to the receptor-triggered conformational change in HIV gp120/gp41?